Taxane-Induced Neuropathy and Its Ocular Effects—A Longitudinal Follow-up Study in Breast Cancer Patients

Stache, Nadine; Bohn, Sebastian; Sperlich, Karsten; George, Christian; Winter, Karsten; Schaub, Friederike; Do, Ha-Vy; Röhlig, Martin; Reichert, Klaus-Martin; Allgeier, Stephan; Stachs, Oliver; Stachs, Angrit; Sterenczak, Katharina A

doi:10.3390/cancers15092444

Cited by 2 publications

(1 citation statement)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ocular neurotoxicity has been hypothesised as neurotoxicity in two small studies. One study found increased retinal thickness in taxaneexposed ESBC patients (137), and another found worse ocular discomfort in patients with TIPN compared to BC survivors without TIPN (138).…”

Section: Other Taxane -Induced Neurotoxicitymentioning

confidence: 99%

Taxane-Induced Peripheral Neuropathy among Early-Stage Breast Cancer Survivors : Prevalence, Risk Factors, Quality of Life and Genetic Prediction Models

Engvall

2024

Linköping University Medical Dissertations

View full text Add to dashboard Cite

Background: Taxane-induced peripheral neuropathy (TIPN) is a common and distressful side effect. Little is known on how long TIPN persist and its effect on health-related quality of life (HRQL). The overall aim of this thesis was to study the prevalence and severity of persistent TIPN, to investigate its impact on HRQL and to explore the clinical and genetic risk factors for TIPN among early-stage breast cancer survivors (ESBCS).Methods: A population-based cohort of 884 recurrence-free ESBCS diagnosed 2010-2015 in the Southeast Health Care region, Sweden and 1768 control women without prior cancer, who received a postal questionnaire including EORTC chemotherapy-induced peripheral neuropathy (CIPN20) and QLQ-C30 instruments. Prevalence of TIPN symptoms and clinical risk factors were explored. Adjusted relative risks (RR) were estimated for ESBCS compared to control women. For impact on HRQL, adjusted mean scores of QLQ-C30 scales among ESBCS with and without TIPN were calculated. Blood samples from 362 ESBCS were whole-exome sequenced. We leveraged logistic regression models to develop and validate polygenic prediction models to estimate the risk of persistent PN symptoms in a training and test cohort.Results: The response rate was 79% for ESBCS and 59% for controls. The median time post-taxane was 3.6 years. The adjusted RR for ESBCS vs. controls was highest (RR 1.8) for tingling in feet and numbness in feet. Individual sensory symptoms occurred in 9%-48% and motor symptoms in 7%-61% of ESBCS. The most prevalent symptoms were difficulty opening jar and cramps in feet. Paclitaxel, older age, overweight, diabetes mellitus, vibrating hand tools, smoking and autoimmune disease were independent risk factors (Study I). All 13 sensory and motor TIPN symptoms at increased risks among ESBCS had a significant impact on global health status, which worsened with increased severity of TIPN. Between 30%-93% of ESBCS with moderate-severe TIPN reported a clinically important impairment of functioning and personal finances. Moderate-severe difficulty climbing stairs and problems standing/walking were associated with medium-large clinically important differences (Study II). In the explorative sub-study, two of five prediction models based on genetic and clinical risk factors obtained Did you have difficulty hearing?Difficulty hearingPlease answer the following question only if you drive a car Did you have difficulty using the pedals? Difficulty using pedals Docetaxel60+Capecitabin900 2 w x 3-4 Concomitant with EC-T 3w, every 3 weeks; 2w, every 2 weeks; EC, Epirubicin-Cyclophosphamide. Note: As suggested in revision of guidelines.Neoadjuvant chemotherapy is the preferred choice in HER2+ and TNBC due to highly proliferative disease, the possibility to evaluate response (26), and since the evidence as to the efficacy of additional treatments is only shown in trials conducted in a neoadjuvant setting. In HER2+ disease, 'Plus' Increase of sensation Tingling, Burning sensation Allodynia, Hyperalgesia Cramps 'Minus' Loss of function Num...

show abstract

Section: Other Taxane -Induced Neurotoxicitymentioning

confidence: 99%

Taxane-Induced Peripheral Neuropathy among Early-Stage Breast Cancer Survivors : Prevalence, Risk Factors, Quality of Life and Genetic Prediction Models

Engvall

2024

Linköping University Medical Dissertations

View full text Add to dashboard Cite

show abstract

A comprehensive study of adverse effects of chemotherapy on female breast cancer patients in NORI Cancer Hospital, Islamabad in a developing country

Abid,

Saeed,

Iftikhar

et al. 2024

J Oncol Pharm Pract

View full text Add to dashboard Cite

Introduction Breast cancer is one of the top three malignancies worldwide. While radiotherapy, hormone replacement therapys, and chemotherapy are treatments, chemotherapy causes adverse effects that hinder daily life activities. Objectives To assess the prevalence, severity, and association of symptomatic toxicities in female breast cancer patients affecting various organ systems post systemic chemotherapy (adjuvant and neoadjuvant), and their impact on daily activities. Additionally, to determine the severity of adverse effects in specific age groups and their association with family history and disease stage. Methodology An observational study was conducted on 253 female breast cancer patients receiving chemotherapy at NORI Cancer Hospital from May to October 2023. Data collection tools included the NCI-PRO-CTCAE standardized questionnaire and patient medical records. Analysis was performed using descriptive statistics, T-tests, and Chi-square tests. Results Among the 253 patients, 41.4% were aged 41–50. Significant weight changes ( p = 0.034) were observed with more than three chemotherapy cycles. Notable associations included increased chemotherapy cycles with gastrointestinal (mouth/throat sores p = 0.031, vomiting p = 0.021), respiratory (cough p = 0.04), cardiovascular (arm/leg swelling p = 0.007, palpitations p = 0.052), integumentary (hair loss p = 0.000, skin dryness p = 0.054), and musculoskeletal (fatigue p = 0.002) adverse effects. Positive family history and the 18–30 age group also showed significant associations with adverse effect severity. Disease stage significantly influenced the nervous system (stage 2 p = 0.007, stage 3 p = 0.01). Conclusion The severity of adverse effects varies among age groups, depending on disease stage, genetics, and treatment duration. These patient-reported outcomes highlight the need for better management strategies considering prognostic factors and treatment adverse effects.

show abstract

Taxane-Induced Neuropathy and Its Ocular Effects—A Longitudinal Follow-up Study in Breast Cancer Patients

Cited by 2 publications

References 54 publications

Taxane-Induced Peripheral Neuropathy among Early-Stage Breast Cancer Survivors : Prevalence, Risk Factors, Quality of Life and Genetic Prediction Models

Taxane-Induced Peripheral Neuropathy among Early-Stage Breast Cancer Survivors : Prevalence, Risk Factors, Quality of Life and Genetic Prediction Models

A comprehensive study of adverse effects of chemotherapy on female breast cancer patients in NORI Cancer Hospital, Islamabad in a developing country

Contact Info

Product

Resources

About